Twist Bioscience (TWST) Cost of Revenue (2017 - 2026)

Twist Bioscience has disclosed Cost of Revenue across 10 years of filings, most recently posting $53.6 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 14.6% year-over-year to $53.6 million; the TTM figure through Mar 2026 stood at $196.3 million (up 5.91% YoY), while the FY2025 annual figure was $185.6 million, up 3.31% from the prior year.
• Cost of Revenue grew to $53.6 million in Q1 2026, from $49.7 million in the prior quarter.
• Over the last five years, Cost of Revenue for TWST reached as high as $53.6 million in Q1 2026 and fell as low as $29.4 million in Q4 2022.
• The 5-year median for Cost of Revenue is $44.4 million (2024), against an average of $42.1 million.
• Annual changes were most pronounced in 2022 — Cost of Revenue surged 56.16% — and 2025, when it fell 3.1%.
• A 5-year view of Cost of Revenue shows it stood at $29.4 million in 2022, then surged by 44.47% to $42.5 million in 2023, then gained by 7.85% to $45.9 million in 2024, then rose by 8.4% to $49.7 million in 2025, then increased by 7.78% to $53.6 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $53.6 million, $49.7 million, and $48.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.